Introduction
Coxiella burnetii is a bacterial pathogen that is widely present in dairy products across the United States and many other parts of the world. C. burnetii DNA has been detected in bovine, ovine and caprine milk, cheeses, yogurt, creams and butters [Reference Eldin1–Reference Pearson4]. Viable C. burnetii has been isolated from hard cheeses made with unpasteurised milk even after 8 months of ripening [Reference Barandika5]. It has been found in 90% of bulk milk tank samples in the United States and unless properly inactivated, viable C. burnetii can survive in refrigerated milk up to 42 months [Reference Kim6, Reference von Sprockhoff7]. Concentrations of C. burnetii in milk can reach as high as 106 cells in one 8 ounce glass [Reference Kim6, Reference Enright, Sadler and Thomas8].
C. burnetii is the causative agent of Q fever in humans and coxiellosis in animals [Reference Maurin and Raoult9, Reference Anderson10]. Q fever can present as an acute febrile illness, hepatitis or pneumonia. It is often self-limiting with a low mortality rate. Chronic Q fever can appear months to years after the initial infection and often manifests as endocarditis or vascular infection. Chronic Q fever endocarditis is fatal without treatment and antibiotic treatment is recommended for at least 18 months [Reference Anderson10]. Infection is most often attributed to inhalation of aerosolised bacteria shed from infected domestic ruminants [Reference Maurin and Raoult9]. Ingestion as an infectious route for C. burnetii has been studied to some degree in goats, dogs, pigeons, rodents and humans [Reference Roest11–Reference Rehacek, Ac and Brezina22]. Despite this, the role of oral transmission remains controversial. Human studies are confounded by the lack of appropriate controls coupled with unknown pathogenicity and dosage of study strains. To date, no studies in rodents have delivered physiologically relevant dosages of C. burnetii directly to the stomachs of immunocompetent animals. Furthermore, virulence amongst different C. burnetii strains can vary drastically [Reference Long23–Reference Sobotta25], and little is known about the pathogenicity of C. burnetii strains currently circulating in dairy products in the United States. As of 2011, the sale of raw milk was legal in 30 states, an increase from 22 in 2004 [Reference David26]. In 2011, an outbreak of Q fever occurred in Michigan, believed to be the result of consuming raw milk [Reference Signs, Stobierski and Gandhi17]. Viable C. burnetii has been isolated from multiple samples of unpasteurised milk across many states [Reference Pearson4, Reference Olivas27].
Three major sequence types (STs) of C. burnetii have recently been identified in the United States by single-nucleotide polymorphism-based analyses [Reference Pearson4, Reference Kersh28]. ST8 is associated with goats and is responsible for multiple outbreaks of Q fever [Reference Kersh28]. ST20, linked to dairy cattle, is widespread in dairy products, while ST16/26s are not closely associated with any one species [Reference Pearson4, Reference Kersh28]. Prior to 2007, no ST20 isolates had been collected in the United States; therefore, little is known about the pathology of these new strains. Given the close species association of C. burnetii strains coupled with the rising popularity of goats and their milk-based products in the United States, we sought to examine whether consumption as a route of infection is possible or strain dependent amongst these relevant sequence types.
Methods
Ethical statement
The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional guides on the care and use of laboratory animals. All animal experiments were performed according to an animal protocol approved by the CDC Institutional Animal Care and Use Committee.
Bacterial strains and growth conditions
The C. burnetii strains used in this study include Nine Mile (NM) phase I (RSA493), an ST16 isolated from a tick in 1935 [Reference Stoker and Fiset29], CM-SC1, an ST20 strain, isolated in 2007 from unpasteurised cow's milk purchased in South Carolina [Reference Pearson4, Reference Olivas27] and GP-CO1, an ST8 strain, isolated in 2007 from the placenta of a goat associated with a human Q fever outbreak located in Colorado [Reference Bamberg30]. Strains were cultured in RK-13 cells and purified by digitonin lysis [Reference Cockrell31]. Stocks were kept frozen at −80 °C in sucrose phosphate glutamate buffer until use.
Mouse infections
Male BALB/c mice, 4–6 weeks of age, were purchased from Charles River Laboratories. This mouse strain is considered intermediately sensitive to C. burnetii infection [Reference Scott, Williams and Stephenson32, Reference Stein33]. Mice were housed in a Tecniplast Isocage system (Tecniplast, Exton, PA) in an ABSL3 facility and given food and water ad libitum. Mice were orogastrically inoculated using a feeding needle to deliver a target inoculum of 1 × 106 genome equivalents (GE) (actual GE administered: 1.24 × 106 of NM, 2.56 × 106 of CM-SC1 and 3.05 × 106 of GP-CO1) in a 100 µl volume of phosphate-buffered saline (PBS). The dosing volume represents 4–5 ml per kg of body weight and was selected to reduce the risk of gavage-related reflux. No animals receiving inoculums via oral gavage (OG) displayed any signs of respiratory distress that would suggest aspiration of dosing material. Mice receiving the same dose of C. burnetii in 100 µl of PBS by intraperitoneal injection (IP) served as positive controls. Negative control mice were given 100 µl of sterile PBS by OG inoculation. The OG-infected, IP-infected and uninfected mice were maintained in separate HEPA-filtered isolator cages. Experiments with the three C. burnetii isolates were carried out independently with four OG-infected mice, two IP-infected mice and two PBS OG mice for each of three time points. Mice were monitored for clinical symptoms and weighed periodically for 21 days post-infection. On days 7, 14 and 21, mice were euthanised and blood was collected by cardiac puncture. Lungs, spleen, liver, stomach, small intestine, caecum and colon were aseptically removed. Spleens were weighed before further processing. Tissues were homogenised in PBS using 3.0 mm triple-pure zirconium beads in a BeadBug 6 microtube homogeniser (Southern Labware, Cumming, GA) with a speed of 7.0 m/s for five 30 s cycles with a 30 s pause between each cycle.
Quantitative polymerase chain reaction (PCR)
To quantify C. burnetii DNA in blood and tissues, total genomic DNA was extracted from 200 µl of blood or homogenised tissues using the QIAamp DNA mini kit (Qiagen, Valencia, CA), according to the manufacturer's instructions. Gut tissues (small intestine, caecum and colon) were processed using the QIAamp Fast DNA Stool mini kit (Qiagen, Valencia, CA), according to the manufacturer's instructions with the following modifications. A 200 µl volume of homogenised tissue was added at a 1:1 ratio with the InhibitEX buffer. Quantitative PCR was performed using primers specific to com1, as previously described [Reference Kersh34]. Cycle threshold (Ct) data for C. burnetii com1 were normalised to murine Actb (Applied Biosystems, Waltham, MA) and normalised cycle threshold values (ΔCt) were transformed using 2−ΔCt/10−6 [Reference Livak and Schmittgen35], and reported as arbitrary quantity units.
Serology
Serum samples were screened for both phase I and phase II anti-C. burnetii immunoglobulin G (IgG) by indirect immunofluorescence antibody test (IFA) as previously described [Reference Schoffelen36]. Blood was separated in a 1.1 ml microtube containing serum gel with a clotting activator (Starstedt, Nϋmbrecht, Germany) at 10 000 g for 5 min. Geometric mean titre (GMT) was calculated as described previously [Reference Miller37].
Statistical analysis
Statistical significance of weight loss and splenomegaly data was determined by Student's t-test. Data were analysed using GraphPad Prism 7.01 software (GraphPad). For all analysis, P < 0.05 was deemed significant.
Results
The NM strain effects weight gain and splenomegaly following oral infection in immunocompetent BALB/c mice
We delivered three different strains of C. burnetii, Nine Mile (NM), CM-SC1 and GP-CO1 directly into the stomachs of BALB/c mice via OG and noted no signs of illness through 21 days post-infection (pi). Among mice given the same inoculums via IP injection, only NM-infected mice displayed ruffled fur from day 4 through day 12. None of the mice died prior to being euthanised. None of the mice infected with CM-SC1 or GP-CO1 displayed decreased weight relative to PBS controls regardless of the administration route (Fig. 1a and b). By day 8 pi, NM IP mice had lost an average of 12.09% while PBS OG control mice had gained 5.47% (P < 0.0001). Although, NM OG mice displayed no weight loss relative to day 0, weight gain was decreased 1.9-fold (P < 0.01) relative to PBS OG mice by day 9 pi.
Splenomegaly was observed in all three strains when delivered via IP albeit with variable timing and intensity (Fig. 1c). The largest increase in percent spleen-to-body weight occurred in NM IP-infected mice across all time points studied, with a 17-fold increase (P < 0.0001) relative to PBS at day 14 pi. Splenomegaly increased across the study period for CM-SC1 IP-infected mice, with an eightfold increase (P < 0.0001) by day 21 pi. The GP-CO1 IP cohort had a sixfold increase (P < 0.0001) at day 7 pi, which fell to 3.3-fold (P < 0.0001) by day 14 pi and was no longer significant relative to PBS OG controls by day 21 pi. Among the mice infected via OG, only NM was capable of inducing significant spleen enlargement with 1.9-fold (P < 0.05), 2.5-fold (P < 0.01) and 1.6-fold (P < 0.01) increases relative to PBS OG for days 7, 14 and 21 pi respectively.
Mice mount a robust immune response against NM and CM-SC1 strains of C. burnetii delivered directly into the stomach
Sera of mice were analysed for the presence of antibodies against C. burnetii phase I (PhI) and phase II (PhII) antigens using IFA. Sera from PBS-treated mice were negative against both antigens at all time points (data not shown). Mice receiving NM orally had no detectible antibodies at day 7 pi; however, all mice seroconverted by day 21 pi with a GMT of 215 (range: 128–1024) for PhI and 8192 (range: 4096–16 384) against PhII (Fig. 2a). Only one of the mice receiving CM-SC1 by OG seroconverted by day 14 pi; however, by day 21 pi all had antibody titres against C. burnetii, with a GMT of 38 (range: 16–64) for PhI and 861 (range: 256–2048) for PhII. Among mice infected with GP-CO1 by OG, only one seroconverted by day 21 pi with a titre of <16 for PhI and 128 for PhII.
The highest antibody titres were observed for mice receiving NM via IP injection with a GMT of 11 585 (range: 8192–16 384) for PhI and 92 682 (range: 65 536–131 072) for PhII by day 21 pi (Fig. 2b). The GMT for CM-SC1 was 4096 (range: 2048–8192) for PhI and 32 768 (range: 32 786–32 768) for PhII by day 21 pi. The lowest titres among IP-injected mice were observed for those receiving GP-CO1 with a GMT of 91 (range: 64–128) for PhI and 8192 (range: 8192–8192) for PhII by day 21 pi.
Coxiella burnetii NM, CM-SC1 and GP-CO1 strains are able to escape the gastrointestinal tract and disseminate to peripheral tissues
Murine blood and tissues were analysed for the presence of C. burnetii DNA using quantitative PCR. Tissues from PBS-treated mice were negative at all time points (data not shown). All mice infected by IP injection had bacterial DNA in the blood at day 7, which decreased throughout the 21-day study period (Fig. 3a). Amongst the cohort of mice infected by OG, no more than one mouse was positive for Coxiella in the blood at any time point tested, regardless of the infecting strain. On days 7 and 14 pi, splenic levels of C. burnetii DNA were highest in NM followed by CM-SC1 and GP-CO1 regardless of the administration route (Fig. 3b). Among IP-infected mice, NM was 15-fold higher and 4000-fold higher by day 7 than CM-SC1 and GP-CO1 infected mice, respectively. For mice infected by OG, splenic bacterial loads were highest for NM at day 7 followed by a 32-fold decrease by day 14. Subsequent to CM-SC1 and GP-CO1 OG infection, the number of positive mice peaked at day 21 with four and two mice, respectively. Similar trends were observed in the liver and lungs for both IP- and OG-infected mice (Fig. 3c and d). Regardless of the infecting strain or the tissue type, mice infected by IP had higher bacterial loads relative to OG-infected mice.
Coxiella burnetii NM and CM-SC1 strains are able to persist in the stomach and mesenteric lymph nodes following oral gavage
To date, no data are available as to whether C. burnetii can persist in the gastrointestinal tract following oral entry. To address this, we analysed tissues of the alimentary system subsequent to OG with NM, CM-SC1 or GP-CO1. Regardless of the infecting strain, C. burnetii DNA was only transiently identified in the small intestine, caecum and colon throughout 21 days pi (Fig. 4a–c). At each time point tested, NM was detected in the mesenteric lymph nodes (MLN) of three of the mice (Fig. 4d). By day 21, MLN of three mice were positive following infection with CM-SC1, while only one GP-CO1 OG mouse had positive MLNs at day 14. As demonstrated in Figure 4e, GP-CO1 and CM-SC1 were identified in stomachs of two of the mice by day 7 and day 21, respectively. Interestingly, NM was detected in the stomachs of all OG mice at every time point and mean quantity increased 2000-fold from day 7 to 21. Gastrointestinal tract tissues from IP-treated mice were positive at all time points, except for the caeca of GP-CO1-infected mice which were positive through day 14 pi (data not shown).
Discussion
We analysed the ability of three strains of C. burnetii to infect immunocompetent BALB/c mice when introduced directly into the stomach. The three strains, Nine Mile (ST16), CM-SC1 (ST20) and GP-CO1 (ST8) comprise the three major sequence types of C. burnetii currently circulating in the United States [Reference Pearson4, Reference Kersh28]. All three strains led to infection in mice following OG, evidenced by the ability to detect C. burnetii DNA in tissues coupled with an antibody response (IFA; PhII titre of >32). These findings indicate that the oral route is a viable route of transmission for these strains. Each strain was also injected into the peritoneal cavity of mice at the same dose, which resulted in more severe disease in all three strains. These findings demonstrate that only a portion of the Coxiella are able to transition from the gastrointestinal tract and disseminate. Further studies are needed to determine whether this decrease in pathology relative to IP is dose dependent and how OG relates to aerosol challenge.
We demonstrate herein that C. burnetii is present in the stomachs of mice 21 days after oral entry and that the level of gastric NM increased dramatically over the study period. These findings suggest that C. burnetii is able to avoid elimination by peristalsis, invade the gastric epithelium and replicate; however, the mechanism by which this occurs remains to be determined. Furthermore, it is unclear whether Coxiella localises to specific regions within the stomach and how long it is able to persist. These findings raise concerns regarding repeated exposure through continued consumption of raw milk, which may support colonisation of the stomach. Similar to other enteropathogenic bacteria such as Salmonella enterica serovar Typhimurium, Yersinia enterocolitica and Yersinia pseudotuberculosis, C. burnetii is capable of colonising the MLNs in orally infected mice, suggesting that Coxiella is able to penetrate the intestinal epithelial barrier [Reference Gaines38–Reference Miller40]. Work with the NM strain in bovine intestinal epithelial cells in vitro showed enhanced susceptibility to invasion by C. burnetii relative to lung and placental epithelial cell lines; however, replication within the intestinal cells was limited [Reference Sobotta41]. The mechanism by which Coxiella escapes the gastrointestinal tract is not understood.
We observed varying degrees of virulence amongst the three strains tested; however, this was independent of the administration route. Infection with the well-characterised laboratory strain, Nine Mile, resulted in more severe disease based on all aspects examined. This strain was originally isolated from a tick in 1935 and has since been passaged in guinea pigs 307 times [Reference Stoker and Fiset29]. It is possible that these methods have led to adaptation of this strain to rodents, which may account for the increased pathogenicity relative to CM-SC1 and GP-CO1, which have only been passaged one to two times in mice. CM-SC1 belongs to the sequence type 20, which is widespread in cattle across the United States, while GP-CO1 belongs to the goat-associated ST8s. Despite the ST8s being frequently linked to Q fever outbreaks in the United States, GP-CO1 was the least virulent of the strains tested. It is possible that ST8 strains are less likely to induce a robust immune response, thereby allowing for long-term persistence in the host. This is supported by the drastically reduced phase I specific antibody titres observed in GP-CO1 infected mice relative to CM-SC1, despite having comparable bacterial loads in the blood (Fig. 1a and 2). In the absence of additional test strains within each sequence type, it is not possible to demonstrate conclusively that virulence is distinct among these groups. However, these strains show remarkably consistent species association and in vitro growth characteristics, which supports the notion that they may have similar characteristics in vivo as well [Reference Pearson4, Reference Kersh28]. Furthermore, similar patterns of virulence were observed in a study utilising a guinea pig IP model, where NM and another ST16, Ohio, were determined to be the most virulent, followed by Q195, an ST20, and finally the ST8s, Q238 and Priscilla [Reference Long23]. Further studies are needed to determine whether these findings are representative of each sequence type and whether the pathogenicity observed herein is consistent following aerosol challenge.
Disclaimer
The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the CDC.
Conflict of interest
No competing financial interests exist.